Click on a filter below to refine your search. Remove a filter to broaden your search.
The controversy over aducanumab (Aduhelm) stretches back to its June 2021 approval by the US Food and Drug Administration.
CMS says a final decision on coverage is not likely until next spring.
The announcement comes shortly after Aduhelm maker Biogen cut the price of the drug by about half, from $56,000 to $28,000 a year.
The decision is meant to protect patients while gathering more clinical data on whether the medication actually helps slow declines in thinking.